News

Lack of sleep can induce flare-ups, creating a vicious cycle and putting patients at risk of serious additional health challenges.

The news comes shortly after a YouGov poll found that 81% of HCPs think that general analysis of data would help enable quicker diagnosis and more effective treatment.

Despite the majority of healthcare professionals thinking that general analysis of data would help enable quicker diagnosis, most don’t trust “big tech” companies to do it.

The treatment reduced haemoglobin A1c by 0.19% and LDL-C by 25% in those not on statin background therapy.

The gadolinium-enhanced MRI requirement in the previous NICE guidance was a “significant barrier” for many clinicians and their patients.

$1m of the funding will go in to AI and drug discovery resources per disease project.

The company intends to file a Marketing Authorisation Application (MAA) in the first half of next year, based on Phase II and III trials.

The acquisition was decided on the back of The Medicines Company’s inclisiran trials.

The results mark the first time in a decade that a treatment has improved overall survival for the indication.

Currently, a significant number of patients deemed “at risk” are implanted with implantable cardioverter-defibrillators that are never needed, which can be severely detrimental to their overall health.

The approval was based on positive results from the interim analyses of two Phase III clinical trials, ELEVATE-TN and ASCEND.

The Party’s manifesto puts emphasis on investing in the NHS and increasing expenditure across the health sector, but the BMA says the promises are not enough.

The specialist HIV company has signed an exclusive licensing agreement for an investigational broadly neutralising antibody (bNAb) – N6LS.